Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 11/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 11/20 | 0.48 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732464 | 0.85 | NTSR1 (0.43) | CYP1A1CYP1B1PFKFB3MAOBSNCA | |
| SCHEMBL3732309 | 0.82 | CYP1A1 (0.68) | CYP1A1CYP1B1MAOBP4HBSNCA | |
| SCHEMBL3735792 | 0.78 | NTSR1 (0.50) | CYP1A1CYP1B1PFKFB3RAB9ASNCA | |
| SCHEMBL3735484 | 0.77 | PTGS2 (0.48) | CYP1A1CYP1B1MAOBP4HBSNCA | |
| SCHEMBL3733158 | 0.77 | P4HB (0.46) | CYP1A1CYP1B1MAOBP4HBCXCL12 | |
| SCHEMBL3742795 | 0.77 | APLNR (0.41) | CYP1A1CYP1B1PFKFB3P4HBSNCA | |
| SCHEMBL3732308 | 0.77 | CYP1A1 (0.68) | CYP1A1CYP1B1MAOBP4HBCXCL12 | |
| SCHEMBL3737992 | 0.73 | NTSR1 (0.54) | CYP1A1CYP1B1MAOBP4HBSNCA | |
| SCHEMBL3735640 | 0.73 | NTSR1 (0.56) | CYP1A1CYP1B1RAB9AP4HBSNCA | |
| SCHEMBL8160897 | 0.73 | NTSR1 (0.56) | CYP1A1CYP1B1RAB9AP4HBSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | CYP1A1 1184/4885CYP1B1 976/4885PFKFB3 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.